Pregnant patients experiencing miscarriage who live in states with abortion bans have fewer options for health-care management, according to a new study published by the Journal of the American Medical Association.

The study, published May 18, 2026 found a shift away from managing miscarriages with a two-drug approach that includes mifepristone—which has been the subject of numerous legal battles that are still playing out in federal courts—and toward approaches that include only misoprostol, which has a lower rate of effectiveness.

The states with abortion bans had a nearly 3 percent increase in expectant management, the study showed, which means a health provider monitors the condition without prescribing any form of treatment to see whether the condition resolves without intervention. The study was conducted by researchers in the Department of Obstetrics and Gynecology at Oregon Health and Science University.

Among those patients who received medication, there was a nearly 14 percent increase in the use of misoprostol-only regimens, which goes against the American College of Obstetricians and Gynecologists’ recommendation of using a combination of mifepristone and misoprostol as the most........

© Rewire.News